“In Prime Minister Modi’s vision of ‘Viksit Bharat’ by 2047, analytical instrumentation and life-sciences innovation are foundational. IAIA’s 29-year journey reflects our commitment to building the right ecosystem—partnering with global OEMs, government bodies, and research institutes—to ensure India leads in scientific instrumentation, quality systems, and digital laboratories. With Spinco’s 44-year legacy of bringing world-class technologies to Indian scientists, and IAIA’s policy advocacy and training initiatives, we are confident that India will realize its full potential as a global leader in analytical science.”
—Ravindranath Cherukuri
Ravindranath Cherukuri, Managing Director, Spinco Group of Companies, is a veteran leader in India’s analytical instruments and life-sciences sector, currently serving as President of the Indian Analytical Instruments Association (IAIA) since 2024. With over 22 years of experience in corporate governance and technical distribution, he heads the Spinco Group—comprising Spinco Technologies/Spincotech Private Limited in Hyderabad and Spinco Biotech Private Limited in Chennai—where he oversees the distribution of chromatography, mass spectrometry, and laboratory automation solutions. Under his stewardship, Spinco has forged strategic partnerships with global technology leaders such as Shimadzu (awarded “Best Distributor” 2022–23) and Daicel Chiral Technologies. As IAIA President, he co-organizes analytica Lab India with MesseMünchen, elevating it to South Asia’s premier platform for laboratory innovation and policy advocacy.
In an exclusive interview with Rashmi Kumari of Neo Science Hub during analytica India Lab 2025, Mr. Cherukuri emphasized India’s rapidly expanding analytical instruments market, the critical role of indigenous manufacturers, and IAIA’s commitment to advancing digital compliance, sustainability, and global technology adoption.
IAIA has grown from 10 founding members to co-organizer of South Asia’s premier lab-tech expo. How do you see India’s ₹14,000-15,000 crore analytical instruments market evolving toward global integration by 2030? What role will Indian manufacturers play versus multinationals?
India’s analytical instrumentation market—currently valued at around $1.7–2 billion (₹14–15 thousand crore)—is on track to more than double by 2030. This growth is driven by expansions in pharma, diagnostics, and chemical industries, plus our demographic edge with a young talent pool. As India becomes the pharmacy and biologics capital of the world, domestic manufacturers will scale up through strategic government incentives—such as recent GST reductions—and synergy with global technology leaders. While multinationals will continue direct operations here, indigenous firms will increasingly localize manufacturing, R&D, and after-sales support to compete on cost, customization, and rapid service.
Pharmaceutical firms now demand CFR Part 11 compliance, robust data-integrity frameworks, and real-time audit readiness. How is IAIA bridging the technology-regulation gap for smaller labs that struggle to adopt advanced systems despite clear ROI?
IAIA is spearheading policy advocacy and training initiatives to help SMEs adopt compliant technologies. We’re collaborating with regulators to streamline validation guidelines and reduce paperwork burdens for small labs. Through our Centers of Excellence at IITs and IISERs, we provide hands-on workshops on software-integrated digital labs—covering LIMS, ELN, and QMS solutions that ensure CFR Part 11 compliance. We’re also partnering with software vendors to offer tiered subscription models and shared-services testbeds, enabling cost-effective access to real-time audit-ready platforms with proven ROI.
This year’s “Zero Loss Philosophy” and green-lab showcases demonstrated 60% solvent savings and 90% reduction in paper usage. What policy measures will you advocate to help mid-sized pharma companies overcome the capital-investment barrier to adopt these environmental technologies?
IAIA is proposing a Green Innovation Fund under the Ministry of Chemicals & Fertilizers to subsidize capital costs for sustainable lab upgrades—such as solvent-recycling chromatographs and digital paperless labs. We’re negotiating tax incentives and accelerated depreciation for green instrumentation. Additionally, we plan to launch a “Green Lab Certification” in collaboration with BIS, rewarding mid-sized manufacturers for measurable reductions in solvent and paper waste. This certification will enhance their market credibility, incentivizing further investment.
Despite rapid global innovation in areas like FT-NIR and AI-driven analytics, Indian QC labs face a 3–5 year adoption lag. As Shimadzu’s top distributor and IAIA President, what concrete steps will you implement to narrow this gap?
We’re establishing an “Analytical Technology Accelerator” consortium—uniting IAIA members, OEMs, and major pharma houses—to co-fund pilot deployments of FT-NIR, Raman, and AI-powered software in live QC environments. This will generate local validation data and best-practice protocols within 12 months. We’re also rolling out a “Train-the-Trainer” program with JAIMA and IPMMA to build a network of certified application specialists who can rapidly roll out these technologies in regional hubs. By sharing aggregated performance metrics and user feedback, we’ll accelerate both awareness and confidence among Indian labs.
